Aclacinomycin A hydrochloride |
| Catalog No.GC35238 |
Chlorhydrate d'aclacinomycine A (chlorhydrate d'aclarubicine), une molécule fluorescente et le premier inhibiteur non peptidique décrit présentant une spécificité discrète pour l'activité CTRL (chymotrypsine-like) du protéasome 20S. Le chlorhydrate d'aclacinomycine A est également un double inhibiteur de la topoisomérase I et II. Un agent chimiothérapeutique anthracycline efficace pour les cancers hématologiques et les tumeurs solides.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 75443-99-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Aclacinomycin A hydrochloride (Aclarubicin hydrochloride), a fluorescent molecule and the first described non-peptidic inhibitor showing discrete specificity for the CTRL (chymotrypsin-like) activity of the 20S proteasome[1]. Aclacinomycin A hydrochloride is also a dual inhibitor of topoisomerase I and II[2]. An effective anthracycline chemotherapeutic agent for hematologic cancers and solid tumors[3]. 20S proteasome[1].Topoisomerase I and II[2].
[1]. Isoe T, et al. Inhibition of different steps of the ubiquitin system by CDDP and aclarubicin. Biochim Biophys Acta. 1992 Sep 15;1117(2):131-5. [2]. Hajji N, et al. Induction of genotoxic and cytotoxic damage by aclarubicin, a dual topoisomerase inhibitor. Mutat Res. 2005 May 2;583(1):26-35. [3]. Iihoshi H, et al. Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells. Toxicol Lett. 2017 Aug 5;277:109-114.
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *